Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;74(8):1413-1429.
doi: 10.1007/s00018-016-2407-7. Epub 2016 Nov 4.

Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

Tian Li  1   2 , Shuai Jiang  3 , Zhi Yang  2 , Zhiqiang Ma  4 , Wei Yi  5 , Dongjin Wang  6 , Yang Yang  7   8
Affiliations
Review

Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

Tian Li et al. Cell Mol Life Sci. 2017 Apr.

Abstract

5'-AMP-activated protein kinase (AMPK) is a pivotal regulator of endogenous defensive molecules in various pathological processes. The AMPK signaling regulates a variety of intracellular intermedial molecules involved in biological reactions, including glycogen metabolism, protein synthesis, and cardiac fibrosis, in response to hypertrophic stimuli. Studies have revealed that the activation of AMPK performs a protective role in cardiovascular diseases, whereas its function in cardiac hypertrophy and cardiomyopathy remains elusive and poorly understood. In view of the current evidence of AMPK, we introduce the biological information of AMPK and cardiac hypertrophy as well as some upstream activators of AMPK. Next, we discuss two important types of cardiomyopathy involving AMPK, RKAG2 cardiomyopathy, and hypertrophic cardiomyopathy. Eventually, therapeutic research, genetic screening, conflicts, obstacles, challenges, and potential directions are also highlighted in this review, aimed at providing a comprehensive understanding of AMPK for readers.

Keywords: AMP; Cardiomyocyte; Glycogen storage; Metformin.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Structure of AMPK subunits. AMPK is a heterotrimeric complex of α, β, and γ subunits. The main functions are catalysis, regulation, and conjunction in α, β, and γ subunits, respectively. The α subunit is composed of a kinase domain, an auto-inhibitor domain (AID), and a α-subunit carboxy-terminal domain (α-CTD). The β subunit consists of β-CTD and CBM and functions as the ‘bridge’ between the α and the γ subunits via β-CTD. The γ subunit has N-terminal domain (NTD) and four tandem repeats of cystathionine β synthase (CBS) to form Bateman domains
Fig. 2
Fig. 2
Activity of AMPK heterotrimeric complex. Special site and upstream pharmacologic agonist can regulate the activity of AMPK. Phosphorylation of ST loop suppresses the connecting of agonists to AMPK and downregulates AMPK activity. AMP and phosphorylation of Thr site can enhance the activity of AMPK to >10-fold and >100-fold than basis, respectively
Fig. 3
Fig. 3
Regulation of AMPK in cardiomyopathy. Cardiac hypertrophy is characterized by increased protein synthesis, glucose storage, fibrosis, and impaired cardiac contraction. AMPK is a key regulator for suppressing hypertrophic stimuli and maintaining the integrity of cardiomyocytes. The activation of AMPK is able to inhibit protein synthesis, glucose storage, and fibrosis, and to improve cardiac fibrosis to ameliorate hypertrophic process and keep a better cardiac function
Fig. 4
Fig. 4
Schematic of PRKAG2 cardiomyopathy and HCM. PRKAG2 cardiomyopathy and HCM are two different cardiomyopathy and have its own characteristic. The dominant mutation in the γ2 regulatory subunit of AMPK on chromosome 7q3 may cause PRKAG2 cardiomyopathy manifesting as glycogen overload, ventricular preexcitation, and WPWs. HCM is caused by more than 11 gene mutations and characterized with ventricular preexcitation, WPWs, sarcomeres mutation, and myofibrillar disarray, which can be attenuated by endogenous or exogenous AMPK. It is a little hard to distinguish PRKAG2 cardiomyopathy from HCM in clinic and sometimes need genetic screening for help
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics C, Stroke Statistics S (2016) Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133:e38–e360 - PubMed
    1. Mortality GBD, Causes of Death C (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–171 - PMC - PubMed
    1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart A, Council on Clinical Cardiology HF, Transplantation C, Quality of C, Outcomes R, Functional G, Translational Biology Interdisciplinary Working G, Council on E, Prevention (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807–1816 - PubMed
    1. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381:242–255. doi: 10.1016/S0140-6736(12)60397-3. - DOI - PubMed
    1. Sternick EB, de Almeida Araujo S, Rocha C, Gollob M. Myocardial infarction in a teenager. Eur Heart J. 2014;35:1558. doi: 10.1093/eurheartj/ehu015. - DOI - PubMed

MeSH terms